Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q2)Sep 30, 2025 | (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q4)Mar 31, 2025 | (Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 54.34%-79.22K | -202.83%-39.26K | 10.78%-808.93K | -10,348.88%-911.77K | 141.53%238.16K | -43.13%-173.49K | 118.78%38.18K | 14.87%-906.66K | 94.02%-8.73K | -4.87%-573.41K |
| Net income from continuing operations | 65.52%-173.24K | 83.60%-200.62K | 34.32%-2.17M | 62.62%-384.13K | 66.27%-57.88K | -34.06%-502.44K | 29.15%-1.22M | 44.58%-3.3M | -116.98%-1.03M | -128.18%-171.58K |
| Operating gains losses | -101.18%-10.12K | -186.31%-12.92K | 27.00%1.37M | -117.83%-12.44K | 126.80%514.03K | 46.39%855.58K | -92.50%14.97K | -49.10%1.08M | -30.70%69.77K | -73.70%226.65K |
| Asset impairment expenditure | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --229.93K | ---- | ---- |
| Unrealized gains and losses of investment securities | --0 | --0 | --0 | -99.79%215 | -32.53%-478.02K | -45.82%-540.03K | -9.13%1.02M | -85.46%493.37K | -84.70%104.26K | 63.49%-360.68K |
| Deferred tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Other non cashItems | ---6.52K | ---14.8K | -339.58%-223.07K | -104.37%-7.09K | -234.48%-206.66K | ---- | ---- | 1,367.12%93.11K | --162.24K | ---61.78K |
| Change In working capital | 387.37%110.65K | -17.20%189.08K | -57.82%209.42K | -212.30%-508.32K | 326.53%466.68K | -42.47%22.7K | 8.55%228.36K | 1,592.75%496.49K | 238.54%452.65K | 39.63%-206.01K |
| -Change in receivables | -125.82%-3.82K | -22.27%134.38K | 160.07%50.24K | 99.82%-42 | -4.86%-137.41K | 117.47%14.81K | 169.00%172.88K | -221.78%-83.64K | 80.47%-23.69K | -24,811.03%-131.03K |
| -Change in prepaid assets | 0.03%3.09K | 0.00%3.09K | 150.27%12.38K | -95.26%3.09K | 103.44%3.09K | --3.09K | 2,191.85%3.09K | -180.26%-24.62K | 552.76%65.25K | -2,068.15%-90K |
| -Change in payables and accrued expense | 2,220.18%111.39K | -7.06%51.6K | -75.25%150.09K | -225.40%-511.38K | 2,366.35%601.15K | -79.45%4.8K | -63.22%55.52K | 540.60%606.5K | 69.93%407.81K | 107.24%24.37K |
| -Change in other current liabilities | ---9 | 100.29%9 | -87.13%-3.29K | --0 | 98.35%-154 | --0 | 37.18%-3.13K | -134.83%-1.76K | -34.83%3.29K | ---9.35K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 54.34%-79.22K | -202.83%-39.26K | 10.78%-808.93K | -10,348.88%-911.77K | 141.53%238.16K | -43.13%-173.49K | 118.78%38.18K | 14.87%-906.66K | 94.02%-8.73K | -4.87%-573.41K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -119.35%-64.64K | -169.22%-120.41K | -430.26%-776.98K | -4.76%10.83K | -188.26%-1.3M | 68.32%334.12K | -63.37%173.96K | 141.43%235.27K | -20.14%11.37K | 45.68%-449.55K |
| Net PPE purchase and sale | -24.79%-64.64K | -211.54%-120.41K | -70.11%-1.52M | 49.30%-46.4K | -111.32%-1.38M | ---51.8K | 73.75%-38.65K | 63.03%-891.95K | 62.92%-91.51K | 40.87%-653.22K |
| Net investment purchase and sale | --0 | --0 | 18.03%740.28K | -44.38%57.23K | -58.50%84.53K | 94.41%385.92K | 74.05%212.61K | -66.00%627.21K | -60.58%102.88K | -26.48%203.67K |
| Net other investing changes | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --500K | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -119.35%-64.64K | -169.22%-120.41K | -430.26%-776.98K | -4.76%10.83K | -188.26%-1.3M | 68.32%334.12K | -63.37%173.96K | 141.43%235.27K | -20.14%11.37K | 45.68%-449.55K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 190.14%144.09K | 174.26%157.89K | 137.60%1.59M | 1,009.42%890.44K | -4.11%1.07M | -116.04%-159.86K | 22.56%-212.6K | -46.70%667.6K | -182.82%-97.91K | -19.46%1.11M |
| Net issuance payments of debt | ---- | ---- | --22K | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Net common stock issuance | ---- | ---- | 57.17%1.93M | --500K | 5.56%1.43M | --0 | --0 | -24.82%1.22M | --0 | -17.13%1.35M |
| Net other financing activities | 190.14%144.09K | 174.26%157.89K | 35.24%-360.8K | 476.29%368.44K | -51.20%-356.78K | -116.04%-159.86K | -42.40%-212.6K | -48.02%-557.17K | -182.82%-97.91K | 3.99%-235.96K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 190.14%144.09K | 174.26%157.89K | 137.60%1.59M | 1,009.42%890.44K | -4.11%1.07M | -116.04%-159.86K | 22.56%-212.6K | -46.70%667.6K | -182.82%-97.91K | -19.46%1.11M |
| Net cash flow | ||||||||||
| Beginning cash position | --0 | 20.05%1.78K | -71.92%1.48K | -87.31%12.28K | -68.45%1.79K | -57.05%1.02K | -71.92%1.48K | -98.63%5.28K | 415.04%96.75K | -42.85%5.67K |
| Current changes in cash | -69.13%238 | -283.19%-1.78K | 107.83%297 | 88.98%-10.5K | -88.48%10.49K | -76.64%771 | 84.04%-464 | 99.00%-3.79K | -605.17%-95.27K | 927.09%91.08K |
| End cash Position | -86.69%238 | --0 | 20.05%1.78K | 20.05%1.78K | -87.31%12.28K | -68.45%1.79K | -57.05%1.02K | -71.92%1.48K | -71.92%1.48K | 415.04%96.75K |
| Free cash from | 36.15%-143.86K | -33,798.94%-159.66K | -29.33%-2.33M | -855.91%-958.17K | 6.88%-1.14M | -85.86%-225.29K | 99.87%-471 | 48.28%-1.8M | 74.48%-100.24K | 25.72%-1.23M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.